JumpCan

JumpCan Pharmaceutical (stock code: 600566) recently announced it has formally signed a collaboration agreement with thederma, granting JumpCan Pharmaceutical exclusive commercialization rights for thederma's Benvitimod Cream (Zelimei) in the People's Republic of China (excluding the Hong Kong and Macao Special Administrative Regions and Taiwan, China). This collaboration not only marks another major expansion of JumpCan Pharmaceutical's product pipeline in the pediatric sector and further consolidates its leading position in pediatric therapeutics, but also demonstrates JumpCan Pharmaceutical's firm determination to continue deploying and making breakthroughs in the dermatology innovation field.

As the world's first globally approved topical aryl hydrocarbon receptor (AhR) modulator for treating atopic dermatitis (eczema) in children aged 2 years and older and adults, Zelimei fills the global gap in non-hormonal topical treatment for eczema in young children. By inhibiting inflammatory responses and repairing the skin barrier, the drug achieves therapeutic breakthroughs while ensuring safety, effectively addressing the clinical pain points of traditional treatment regimens — including limited efficacy, obvious side effects, and easy relapse upon discontinuation — offering safer and more effective treatment options for pediatric and adult eczema patients.

This collaboration is an important strategic move for JumpCan Pharmaceutical to deepen its strategic layout in pediatrics and dermatology. As one of the leading pharmaceutical enterprises in the pediatric field, JumpCan Pharmaceutical has deep market experience, a mature marketing network, and strong brand influence. thederma has globally leading innovation capabilities and technological expertise in AhR target research and development. The combination of both parties' strengths will achieve complementary advantages and synergistic empowerment, accelerating the clinical deployment of innovative drugs in the pediatric and dermatology fields and benefiting more patient families.

Cao Wei, General Manager of JumpCan Pharmaceutical Group, stated: "JumpCan Pharmaceutical's partnership with thederma is not only a strategic collaboration based on deep mutual recognition, but also a critical strengthening of the company's product layout in the pediatric and dermatology therapeutic areas. Zelimei fills the clinical treatment gap for young children with atopic dermatitis while demonstrating the hard-core strength of Chinese innovative drugs ranked among the world’s front runners in dermatology. In the future, leveraging JumpCan Pharmaceutical's mature and comprehensive pediatric and dermatology sales network and professional academic promotion team, we will accelerate the market launch and clinical adoption of Zelimei, ensuring that this excellent therapy benefits more atopic dermatitis patients. This will further improve the company's product matrix in pediatrics and dermatology, and continuously inject JumpCan's strength into the advancement of skin health for Chinese children and adults."

Chen Genghui, CEO of thederma, stated: "This strong alliance with JumpCan Pharmaceutical is a key step in strategic synergy and resource complementarity for both parties. Behind the milestone breakthrough of Zelimei — born in China, benefiting the world — lies thederma's persistent original innovation in the AhR target space. We firmly believe that entrusting the Chinese market promotion and clinical adoption of Zelimei to JumpCan Pharmaceutical — which possesses an outstanding commercialization system and deep market capabilities in pediatrics and dermatology — as an important component of the drug's global commercialization will maximize the release of its innovative value. This collaboration is not only the landing of a product, but also a new starting point for both parties to jointly lead the upgrade of treatment standards and reshape the therapeutic landscape for atopic dermatitis. We look forward to joining hands with JumpCan Pharmaceutical to accelerate innovative drugs in serving a wider patient population and contributing more Chinese strength to skin health."

About Benvitimod Cream (Zelimei):

Benvitimod Cream (Zelimei) is an innovative drug independently developed in China with an entirely new mechanism of action and target. It is also the world's first aryl hydrocarbon receptor modulator approved for the treatment of eczema (atopic dermatitis) in children aged 2 years and older and adults. It can simultaneously inhibit inflammatory factors and repair the skin barrier, providing good efficacy and high safety, and resolves the core pain points of traditional atopic dermatitis treatment. Meanwhile, Zelimei fills the gap in non-hormonal topical treatment for young eczema patients, providing safer and more effective solutions for treating eczema on children's facial and delicate skin areas.

About thederma:

Shanghai thederma Medical Technology Co., Ltd. is a biopharmaceutical enterprise driven by original innovation and dedicated to cutting-edge global targets. The company has long focused on pioneering research on the aryl hydrocarbon receptor (AhR), a key immune regulatory pathway. Leveraging its deep expertise and leading technology platform in the AhR target area, thederma has successfully brought the AhR modulator Zelimei to market, achieving a major transformation from scientific discovery to clinical value.

With the commercialization of Zelimei as a starting point, thederma is accelerating the development of its rich AhR-targeted innovation pipeline. The company will continue to expand the therapeutic potential of this target in multiple refractory autoimmune and inflammatory diseases, including vitiligo, alopecia areata, psoriasis, and inflammatory bowel disease — areas with vast unmet clinical needs. thederma aims to build an AhR modulator product matrix covering multiple indications, lead the upgrade of treatment paradigms for immune and inflammatory diseases, and provide better solutions for patients worldwide.

About JumpCan Pharmaceutical:

JumpCan Pharmaceutical (600566.SH) is a national-level high-tech enterprise and national technology innovation demonstration enterprise integrating product R&D, manufacturing, and commercial operations. It ranks among the Top 100 Chinese Pharmaceutical Industrial Enterprises and the Top 10 Most Valuable Listed Pharmaceutical Companies for Investment in China. Our main business covers pharmaceuticals and cosmetics & toiletries, focusing on core therapeutic areas including respiratory, pediatrics, gastroenterology, women's health, dermatology, and cardiovascular diseases. We hold multiple nationally exclusive varieties and dosage forms with a leading market position.

Guided by the purpose of "Build a Joyful and Vibrant Life Together", we are oriented toward clinical medication needs and everyday health demands, providing accessible and diversified solutions to help improve people's lives and give back value to society.